Teacher Retirement System of Texas Sells 3,112 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Teacher Retirement System of Texas reduced its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 10.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 27,700 shares of the company's stock after selling 3,112 shares during the period. Teacher Retirement System of Texas' holdings in Neurocrine Biosciences were worth $3,064,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of NBIX. Vontobel Holding Ltd. grew its holdings in shares of Neurocrine Biosciences by 17.8% during the first quarter. Vontobel Holding Ltd. now owns 9,943 shares of the company's stock valued at $1,100,000 after buying an additional 1,501 shares during the last quarter. Smallwood Wealth Investment Management LLC acquired a new position in shares of Neurocrine Biosciences during the first quarter valued at about $34,000. Peregrine Capital Management LLC grew its holdings in shares of Neurocrine Biosciences by 12.5% during the first quarter. Peregrine Capital Management LLC now owns 72,972 shares of the company's stock valued at $8,071,000 after buying an additional 8,132 shares during the last quarter. Robeco Institutional Asset Management B.V. grew its holdings in shares of Neurocrine Biosciences by 10.8% during the first quarter. Robeco Institutional Asset Management B.V. now owns 16,220 shares of the company's stock valued at $1,794,000 after buying an additional 1,586 shares during the last quarter. Finally, Golden State Wealth Management LLC grew its holdings in shares of Neurocrine Biosciences by 116.9% during the first quarter. Golden State Wealth Management LLC now owns 397 shares of the company's stock valued at $44,000 after buying an additional 214 shares during the last quarter. 92.59% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Neurocrine Biosciences news, Director William H. Rastetter sold 30,000 shares of the business's stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $110.20, for a total value of $3,306,000.00. Following the completion of the transaction, the director owned 37,491 shares of the company's stock, valued at $4,131,508.20. The trade was a 44.45% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jude Onyia sold 20,362 shares of the business's stock in a transaction that occurred on Wednesday, July 2nd. The stock was sold at an average price of $130.13, for a total transaction of $2,649,707.06. Following the completion of the transaction, the insider directly owned 18,289 shares of the company's stock, valued at approximately $2,379,947.57. This represents a 52.68% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 59,975 shares of company stock valued at $7,112,920 in the last quarter. Corporate insiders own 4.80% of the company's stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. JPMorgan Chase & Co. boosted their price target on shares of Neurocrine Biosciences from $183.00 to $184.00 and gave the stock an "overweight" rating in a report on Wednesday, March 26th. UBS Group boosted their price target on shares of Neurocrine Biosciences from $152.00 to $174.00 and gave the stock a "buy" rating in a report on Wednesday. Guggenheim boosted their price target on shares of Neurocrine Biosciences from $155.00 to $165.00 and gave the stock a "buy" rating in a report on Tuesday, May 6th. Wall Street Zen cut shares of Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a report on Thursday, March 20th. Finally, Royal Bank Of Canada restated an "outperform" rating and set a $145.00 price target on shares of Neurocrine Biosciences in a report on Monday, June 2nd. Three analysts have rated the stock with a hold rating and twenty-one have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $163.91.

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock traded down $1.46 during midday trading on Friday, reaching $133.46. 716,610 shares of the stock were exchanged, compared to its average volume of 1,143,821. The company's fifty day moving average is $123.15 and its 200-day moving average is $121.67. The firm has a market cap of $13.21 billion, a PE ratio of 45.24, a PEG ratio of 1.37 and a beta of 0.24. Neurocrine Biosciences, Inc. has a 52 week low of $84.23 and a 52 week high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $0.08 earnings per share for the quarter, missing analysts' consensus estimates of $0.70 by ($0.62). The firm had revenue of $572.60 million for the quarter, compared to the consensus estimate of $587.06 million. Neurocrine Biosciences had a return on equity of 11.81% and a net margin of 12.68%. The business's revenue was up 11.1% on a year-over-year basis. During the same period last year, the company posted $1.20 EPS. On average, sell-side analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.